000			01731nam a2200265 4500
001			ESSALUD
005			20260903155458.0
007			ta
008			t pe ||||| |||| 00| 0 spa d
040			_aBMG
041			_aeng
100			_aFitzgerald, Rebecca C. _eAutor _954609
245			_aBarrett’s Esophagus
300			_apáginas: 1723-1735
520			_aBarrett’s esophagus develops as a result of chronic acid and bile reflux and carries an increased risk of esophageal adenocarcinoma. Because it has no specific symptoms, many patients do not receive a diagnosis or they present with symptoms of gastroesophageal reflux disease and other related risk factors or complications. Diagnosis relies on endoscopic and histopathological findings, including a visible columnar-cell–lined segment measuring at least 1 cm long that contains intestinal metaplasia with goblet cells. Ongoing surveillance focuses on early detection of malignant progression, particularly high-grade dysplasia and early-stage cancer, which allows curative endoscopic treatment and avoids the adverse effects associated with chemotherapy or esophagectomy. Participation in clinical trials is encouraged to improve detection, risk stratification, and management strategies.
650			_aGASTROENTEROLOGÍA GENERAL _954610
650			_aTRATAMIENTOS EN ONCOLOGÍA _953734
650			_aCÁNCER DEL TRACTO GASTROINTESTINAL _953776
650			_aGERIATRÍA _91852
650			_aENVEJECIMIENTO GENERAL _954554
650			_aHEMATOLOGÍA _97422
650			_aONCOLOGÍA GENERAL _954224
773	0		_022717 _922684 _dMassachusetts NEJM Group _oNEJM016 _tThe New England Journal of Medicine _wESSALUD _x0028-4793
942			_cARTICULOS _e2026-08-31 _zsqb
999			_c22936 _d22936